First microreactor permit filed. AI gets its own power plant. BCI moves from communication to cure. Carbon removal finds its template.

NANO Nuclear's university partner submitted the CPA on March 31 — the first application filed under the new Part 53 technology-neutral framework, weeks after the rule was issued.

The KRONOS is a high-temperature gas-cooled microreactor designed for campus-scale deployment, with site characterization already complete.

NANO Nuclear also holds a US Air Force research contract to evaluate KRONOS for energy resilience at a Washington DC military base, signalling parallel defence and commercial pathways.

This is the first real-world test of Part 53 — the new licensing pathway is already being used in practice, not just on paper.

A university site is a strategically smart first deployment: lower political friction, built-in operator training, and a public proof-of-concept for populated-area siting.

If NRC review completes on schedule, KRONOS could enter construction in 2027 — compressing timelines that historically stretched a decade or more.

The CPA filing de-risks the front-end capital stack: NANO Nuclear has passed years of NRC pre-application scrutiny, separating it from earlier-stage competitors.

Second-order demand flows to HALEU fuel supply, microreactor-grade components, and engineering services — sectors that benefit from every CPA entering formal review.

Execution risk remains: NRC timelines can slip, and a construction permit is still several steps from an operating license.

Microsoft secured exclusivity as anchor tenant for the data center campus, with Chevron and Engine No. 1 developing the dedicated behind-the-meter power plant in the Permian Basin.

Seven GE Vernova 7HA gas turbines are already ordered — hardware procurement is ahead of the commercial deal, signalling serious execution intent.

No commercial terms are finalized, but exclusivity signals both parties are sufficiently aligned to block competing negotiations.

This formalizes a new infrastructure financing template: an oil and gas major builds dedicated generation, a hyperscaler anchors it as offtaker, bypassing the strained regional grid entirely.

Permian Basin co-location is strategic — proximity to existing gas supply removes fuel logistics risk and compresses permitting versus greenfield sites.

The behind-the-meter model is spreading fast: Meta is pursuing a similar $3B off-grid structure in Ohio; Google has moved to dedicated gas generation in Texas.

The investable layer is in enabling infrastructure: GE Vernova turbines, power electronics, cooling systems, and specialist engineering firms executing co-located campus builds at gigawatt scale.

Engine No. 1's involvement signals long-duration infrastructure returns, not a short-term trade.

Key risk: no definitive agreement exists yet — exclusivity can collapse, and at 2.5–5 GW, permitting and water rights could add years to timelines.

The FDA granted Breakthrough Device Designation on April 8 for Brain Interchange's use of direct cortical stimulation to restore motor function in chronic stroke patients — an indication no other BCI company currently holds.

Two patients have been implanted under an FDA-approved IDE study at the University of Washington, with the first recovering upper-limb function that had plateaued under conventional therapy.

Brain Interchange is also being evaluated for epilepsy at Mayo Clinic, with paralysis and depression under development — a multi-indication platform strategy.

This separates therapeutic BCI from assistive BCI: most systems enable digital device control; Brain Interchange is engineered to physically restore lost motor function — a fundamentally larger clinical market.

Stroke is the leading cause of acquired long-term disability globally — 9 million ischemic strokes per year, with 50% of patients permanently disabled despite standard rehabilitation.

Breakthrough Designation accelerates the regulatory pathway: prioritized FDA review and more frequent engagement during clinical development.

CorTec's dual business model — proprietary BCI platform plus a CDMO division — provides near-term revenue visibility while the flagship product advances through trials, reducing binary clinical risk.

The multi-indication platform is the key valuation lever: efficacy across stroke, epilepsy, and paralysis expands the total addressable market significantly beyond any single indication.

Risk caveat: Breakthrough Designation does not guarantee approval — larger trials are still required, and the path from two patients to commercial authorization remains long and capital-intensive.

North Star Carbon Solutions LP — a Svante/MLTC joint venture — signed a 15-year offtake with Microsoft for 626,000 tonnes of durable CDR credits from a BECCS project co-located at the MLTC Bioenergy Centre.

Captured CO₂ will be transported and permanently stored in geologic storage owned and operated by North Star, with credits independently verified under applicable carbon removal crediting standards.

Svante is providing all project funding until a construction decision is taken — removing early-stage capital risk from the Indigenous partner and streamlining the path to FID.

Microsoft's anchor offtake de-risks the capital stack, providing the revenue certainty needed to move toward a construction decision — showing how hyperscaler demand can unlock BECCS project finance without policy subsidies.

The Indigenous ownership structure is a replicable template: 100% of distributions flow to MLTC's nine First Nations, aligning carbon removal infrastructure with economic reconciliation.

This is Microsoft's second major BECCS expansion this year — following Stockholm Exergi — signalling active construction of a diversified, geography-spanning durable removal portfolio.

The deal reinforces the project finance model for BECCS: anchor offtake + independent MRV + geologic storage = a bankable structure capable of attracting debt alongside equity.

Second-order opportunities are in the BECCS enabling stack: solid sorbent capture technology, geologic storage operators, biomass logistics, and MRV infrastructure providers.

Risk caveat: BECCS remains scientifically contested — the waste biomass structure here reduces but does not eliminate concerns around upstream emissions and permanence accounting.